Abeona Therapeutics appoints Keith Goldan as new independent Board member and Audit Committee Chair

ABEONA THERAPEUTICS INC.

Board expanded from 9 to 10 members; Goldan appointed as Class 1 director effective April 1, 2026.
Goldan named Chair of Audit Committee; Board determined independence under Nasdaq rules.
Compensation: $50,000 annual cash fee and $150,000 one-time sign-on RSU grant with one-year vesting.
Goldan currently CFO of Syndax Pharmaceuticals; previously CFO at Optinose and Fibrocell.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.